Cenegermin

From WikiProjectMed
Jump to navigation Jump to search
Cenegermin
Names
Trade namesOxervate
Other namesCenegermin-bkbj, recombinant human nerve growth factor (rhNGF), human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer)[1]
Clinical data
Drug classNerve growth factor[2]
Main usesNeurotrophic keratitis[3]
Side effectsEye pain, increased tear production, eyelid pain[3]
Pregnancy
category
  • AU: B3
  • US: N (Not classified yet)
Routes of
use		Eye drop
External links
AHFS/Drugs.comMonograph
MedlinePlusa619001
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Chemical and physical data
FormulaC583H908N166O173S8
Molar mass13267.15 g·mol−1

Cenegermin, sold under the brand name Oxervate, is a medication used to treat neurotrophic keratitis.[3] It is used in those with moderate or severe disease.[3] Use was not recommended by the United Kingdom.[2] It is used as an eye drop.[4]

Common side effects include eye pain, increased tear production, and eyelid pain.[3] Safety in pregnancy is unclear.[2] It is a recombinant form of nerve growth factor (NGF).[2]

Cenegermin was approved for medical use in Europe in 2017 and the United States in 2018.[3][4] In the United States 14 vials costs about 23,600 USD as of 2021.[5]

Medical uses

Dosage

It is used as 1 drop in the affected eye every 2 hours, 6 times per day.[3] It is used for 8 weeks.[3]

History

It was developed by Anabasis Pharma, Dompé Farmaceutici, and Ospedale San Raffaele.[6]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

Research

In addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma.[6]

See also

References

  1. ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1): 76. hdl:10665/330984.
  2. ↑ 2.0 2.1 2.2 2.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1210. ISBN 978-0857114105.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "Oxervate". Archived from the original on 31 October 2020. Retrieved 2 January 2022.
  4. ↑ 4.0 4.1 "Cenegermin-bkbj Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 2 January 2022.
  5. ↑ "Oxervate Prices and Oxervate Coupons - GoodRx". GoodRx. Retrieved 2 January 2022.
  6. ↑ 6.0 6.1 "Cenegermin - Dompe Farmaceutici - AdisInsight". adisinsight.springer.com. Archived from the original on 2020-06-05. Retrieved 2020-06-05.
  7. ↑ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original on 17 September 2020. Retrieved 16 September 2020.

External links

External sites:
Identifiers:
Stub icon

This drug article relating to the nervous system is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Cenegermin&oldid=1376482"